| Title |
Molecular pathways and therapeutic targets in lung cancer
|
|---|---|
| Published in |
Oncotarget, April 2014
|
| DOI | 10.18632/oncotarget.1891 |
| Pubmed ID | |
| Authors |
Emma Shtivelman, Thomas Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno, Ravi Salgia |
| Abstract |
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review. |
Twitter Demographics
The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 33% |
| Italy | 1 | 17% |
| Colombia | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 260 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 3 | 1% |
| Spain | 1 | <1% |
| Japan | 1 | <1% |
| Unknown | 255 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 54 | 21% |
| Student > Master | 43 | 17% |
| Researcher | 28 | 11% |
| Student > Ph. D. Student | 28 | 11% |
| Student > Doctoral Student | 13 | 5% |
| Other | 44 | 17% |
| Unknown | 50 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 58 | 22% |
| Medicine and Dentistry | 50 | 19% |
| Agricultural and Biological Sciences | 44 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 8% |
| Immunology and Microbiology | 6 | 2% |
| Other | 23 | 9% |
| Unknown | 58 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2022.
All research outputs
#4,763,971
of 23,420,064 outputs
Outputs from Oncotarget
#2,084
of 14,409 outputs
Outputs of similar age
#47,106
of 229,576 outputs
Outputs of similar age from Oncotarget
#19
of 118 outputs
Altmetric has tracked 23,420,064 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,409 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.